Show simple item record

dc.contributor.authorFatayer, Hiba
dc.contributor.authorO'Connell, Rachel L
dc.contributor.authorBannon, Finian
dc.contributor.authorColes, Charlotte
dc.contributor.authorCopson, Ellen
dc.contributor.authorCutress, Ramsey I
dc.contributor.authorDave, Rajiv V
dc.contributor.authorGardiner, Matthew D
dc.contributor.authorGrayson, Margaret
dc.contributor.authorHolcombe, Christopher
dc.contributor.authorIrshad, Sheeba
dc.contributor.authorIrwin, Gareth W
dc.contributor.authorO'Brien, Ciara
dc.contributor.authorPalmieri, Carlo
dc.contributor.authorShaaban, Abeer M
dc.contributor.authorSharma, Nisha
dc.contributor.authorSingh, Jagdeep K
dc.contributor.authorWhitehead, Ian
dc.contributor.authorPotter, Shelley
dc.contributor.authorMcIntosh, Stuart A
dc.contributor.authorNeST Study Research Collaborative
dc.date.accessioned2022-06-20T16:17:42Z
dc.date.available2022-06-20T16:17:42Z
dc.date.issued2022-05-11
dc.identifier.issn0007-1323
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338234
dc.description.abstractNeoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.
dc.format.mediumPrint-Electronic
dc.publisherOxford University Press (OUP)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectNeST Study Research Collaborative
dc.titleCurrent practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study.
dc.typeArticle
dc.publisher.departmentDepartment of Oncology
dc.date.updated2022-06-16T19:52:57Z
prism.publicationDate2022
prism.publicationNameBr J Surg
prism.startingPageznac131
dc.identifier.doi10.17863/CAM.85646
dcterms.dateAccepted2022-04-03
rioxxterms.versionofrecord10.1093/bjs/znac131
rioxxterms.versionVoR
dc.contributor.orcidO'Connell, Rachel L [0000-0001-5990-8142]
dc.contributor.orcidColes, Charlotte [0000-0003-4473-8552]
dc.contributor.orcidGardiner, Matthew D [0000-0002-8058-4186]
dc.contributor.orcidPotter, Shelley [0000-0002-6977-312X]
dc.contributor.orcidMcIntosh, Stuart A [0000-0002-4123-9611]
dc.identifier.eissn1365-2168
rioxxterms.typeJournal Article/Review
cam.issuedOnline2022-05-11
cam.depositDate2022-06-16
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International